Increased gene expression of B cell‐activating factor of tumor necrosis factor family, in remitting antineutrophil cytoplasmic antibody‐associated vasculitis patients. (15th December 2021)

• Record Type: Journal Article
• Authors: Jha, Saket; Singh, Jagdeep; Minz, Ranjana W.; Dhooria, Aadhar; Naidu, GSRSNK; Ranjan Kumar, Rajiv; Rathi, Manish; Jain, Sanjay; Anand, Shashi; Sharma, Aman
• Is Part Of: International journal of rheumatic diseases. Volume 25:Number 2(2022)
• Page Start: 218
• Page End: 227
• Publication Date: 2021-12-15
• Subjects: ANCA‐associated vasculitis -- APRIL -- BAFF -- correlation -- gene expression; Rheumatology -- Periodicals; Rheumatology -- Asia -- Periodicals; Rheumatology -- Pacific Area -- Periodicals; Rheumatic Diseases -- Periodicals; Connective Tissue Diseases -- Periodicals; Immune System Diseases -- Periodicals; 616.723
• DOI: 10.1111/1756-185X.14262
• Languages: English
• ISSNs: 1756-1841

Abstract

Abstract: Aim: To study the expression of B cell‐activating factor of tumor necrosis factor family (BAFF) and A proliferation‐inducing ligand (APRIL) genes in active and remitting patients with anti‐neutrophil cytoplasmic antibody‐associated vasculitis (AAV) and healthy controls and their correlation with disease activity. Methods: This was a prospective case‐control study. Gene expressions of BAFF and APRIL were studied in 32 patients with AAV (16 each with active disease and in remission) and 30 healthy age and sex matched controls by real‐time polymerase chain reaction. Results: Out of 32 AAV patients, 26 had granulomatosis with polyangiitis (GPA) and 6 had microscopic polyangiitis (MPA). Mean ages of patients in active (12 GPA and 4 MPA) and remission (14 GPA and 2 MPA) groups were 39.4 ± 17.2 and 44.6 ± 16.1 years, respectively. BAFF gene expression was significantly higher in both the active AAV group and remission AAV group compared to controls ( P < .01). The BAFF expression was significantly higher in AAV patients in remission compared to active AAV patients ( P = .003). In contrast, APRIL expression did not differ between AAV patients and controls ( P = .829). However, APRIL had significantly higher expression in remission as compared to active patients ( P = .048). There was no significant correlation of both BAFF and APRIL expression with disease activity markers (erythrocyte sedimentation rate, C‐reactive protein, platelets and Birmingham Vasculitis Activity Score version 3). Conclusion: BAFF gene is significantly expressed in patients with AAV. Among AAV patients, there is a significantly higher expression of BAFF and APRIL in remitting state of the disease as compared to active state. There is no significant change in APRIL gene expression in patients with AAV as compared to controls. This makes a case for anti‐BAFF therapy in future for AAV patients in northern India.